Phase I and Clinical Pharmacology Study of

to the antifolate drugs trimetrexate, metoprine, homofolate, and CB3717 in human lymphoma and osteosarcoma cells resistant to methotrexate. Cancer. Re...

0 downloads 0 Views 1MB Size

Recommend Documents

Phase I and Clinical Pharmacology Study of Intravenous Flavone Acetic Acid. (NSC347512)1 .... tration was achieved by evaporation under nitrogen. A standard ...

In this Phase I trial, a 1-h or 4-h infusion of the agent was .... under a stream of nitrogen. ... (Model 71OB Wisp; Waters), and chromatography control module.

Nov 8, 2012 - Running Head: Sorafenib, bevacizumab, and cyclophosphamide in solid .... humanized monoclonal antibody that binds directly to all four VEGF ...

was established, bevacizumab dose was escalated. Each course was of 21 ... recombinant, humanized monoclonal antibody that binds directly to all 4 VEGF ...

May 15, 2008 - hamster, and human cells to rBBX-01 (EC50 assay .... avastin; Gem/Dox, generic gemcitabine + pegylated liposomal doxorubicin; HKI-272, ...

Mar 15, 2008 - cycle of therapy was 805/ul and the median platelet nadir was 48,000/ul. Other toxic .... This was achieved using a Waters model 510 pump and ...

Departments of Pediatric Hematology/Oncology, State University of. New York Upstate Medical University, .... Downloaded from ..... Neuro-Oncology, 4: 102–108, 2002. 5. .... Bernstein, M. L. WR-2721 (amifostine) infusion in patients with Ew-.

Val and 5-methylbenzoic acid form the lateral chain. The cycled region ...... (M)/prednisone (P) in men with androgen independent prostate cancer. J Clin Oncol ...

POH was formulated in soft gelatin capsules con- .... Drug Formulation. ... phase I design. .... No significant problems with myelosuppression were seen. Grade 1 ...

(/')determined the human pharmacokinetics of the drug on a. 6-h infusion ..... dexamethasone, and/or aminophylline were required to treat the reactions.

Stevens, S. J. Lee, D. A. Lowenthal, I. Haines, T. D. Walsh,. L. Baltzer ..... potential antitumor agents: a selective screening study. Cancer Treat. Rep.,. 62:45-74 ...

Antisense Oligonucleotide ISIS 3521 Administered in Combination with 5-Fluorouracil and Leucovorin in Patients with. Advanced Cancer1. Sridhar Mani,2 ...

Mar 15, 2008 - nary function defined as a carbon monoxide diffusion capacity of at least 80% of predicted and a ... UV detection was accom plished using a ...

Jul 15, 1995 - Phase I Clinical and Pharmacological Study of Suppression of Human Antimouse. Antibody ... V. V., D. B., H. W., G. H.¡,Laboratory Medicine ¡H.F.], and Clinical Immunology and Biological Therapy [J. L M.],. The University of ....

staurosporine family of agents, which have two indole nitrogens linked to a carbohydrate residue. Representatives from both of these subgroups have been the ...

infusion solutions are compatible with PVC i.v. infusion bags and are chemically stable ... two cycles of treatment. Disease assessments by any tech- ...... Click on "Request Permissions" which will take you to the Copyright Clearance Center's.

anemia, and brief transaminasemia. One patient who received antibody alone had an apparent acute immune complex-mediated reaction. Ten of. 11 patients ...

Heinrich, M. C. SU5416 and SU5614 inhibit kinase activity of wild-type and mutant FLT3 receptor tyrosine kinase. Blood, 100: 2941–2949,. 2002. 8. O'Farrell ...

in Serum of Cancer Patients: Phase I Clinical Trial. Jose A. Baptista,1 ... (1), sub- sequently from. North. American plants of the ganera. Astragulus .... Gal in H20.

Jul 15, 2006 - suggested that G1 arrest induced by EGFR TKI interferes with the cell cycle .... Dassonville O, Formento JL, Francoual M, et al. Expression of ...

derived from breast (MDA-MB-435), colorectal (RKO, HT-29, ..... 2019. 625. 1857. 1077. 4208. 2903. 2434. Ctrough e (ng/ml). Ro 31-7453. 54.2. 145. 72. 361.

control. Clinical Pharmacological Studies. The pharmacokinetic behavior of. IDR was examined using a HPLC method adapted from that of Peng. 2990. Research. ... Compounds were de tected by fluorescence, using excitation and emission wavelengths of. 47

C. G. Haase5, D. Voliotis5 & D. Strumberg2* ... 38-3441 either at doses of 20, 40, 67, 100, 140, 210, 315, 470 and 600mg/m2/day for 1 day every. 3 weeks ..... 38-3441. Plasma samples were analyzed for BAY 38-3441 and CPT using.

Oct 13, 2006 - the adaptation and evaluation of the SFP10–14 ... Twenty-one percent of pupils ... 15–19 years are 16 times more likely to die than those of a ...